tox analysis module in ingenuity pathway analysis (Ingenuity Systems)
90
Structured Review
Ingenuity Systems
tox analysis module in ingenuity pathway analysis
Tox Analysis Module In Ingenuity Pathway Analysis, supplied by Ingenuity Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tox+analysis+module+in+ingenuity+pathway+analysis/tox+analysis+module+in+ingenuity+pathway+analysis/pm34418498-155-20-23
Average 90 stars, based on 1 article reviews
Tox Analysis Module In Ingenuity Pathway Analysis, supplied by Ingenuity Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tox+analysis+module+in+ingenuity+pathway+analysis/tox+analysis+module+in+ingenuity+pathway+analysis/pm34418498-155-20-23
Average 90 stars, based on 1 article reviews
tox analysis module in ingenuity pathway analysis - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
other:Article Title: Bioprinted liver provides early insight into the role of Kupffer cells in TGF-β1 and methotrexate-induced fibrogenesis Article Snippet: Pathways and toxicity lists enriched among statistically significant, differentially expressed genes in the data were identified using the Tox Analysis module in Article Title: Dysregulation of protein degradation pathways may mediate the liver injury and phospholipidosis associated with a cationic amphiphilic antibiotic drug. Article Snippet: Contents lists available at ScienceDirect Toxicology and Applied Pharmacology j ourna l homepage: www.e lsev ie r .com/ locate /ytaap Dysregulation of protein degradation pathways may mediate the liver injury and phospholipidosis associated with a cationic amphiphilic antibiotic drug Merrie Mosedale a, Hong Wu b, C. Lisa Kurtz a, Stephen P. Schmidt b, Karissa Adkins b,⁎,1, Alison H. Harrill a,c,1 a Hamner-University of North Carolina Institute for Drug Safety Sciences, The Hamner Institutes for Health Sciences, Research Triangle Park, NC 27709, USA b Drug Safety Research and Development, Pfizer Global Research and Development, Groton, CT 06340, USA c University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA Abbreviations: MDP, mouse diversity panel; ALT, alan partate aminotransferase; LFT, liver function test; DILI, dr ⁎ Corresponding author at: Drug Safety Research an Research and Development, Eastern Point Rd, Groton, CT E-mail address: Karissa.Adkins@pfizer.com (K. Adkins 1 These two authors contributed equally to this work. http://dx.doi.org/10.1016/j.taap.2014.06.013 0041-008X/© 2014 Elsevier Inc. All rights reserved. a b s t r a c t a r t i c l e i n f o Article Title: Human-relevant mechanisms and risk factors for TAK-875-Induced liver injury identified via a gene pathway-based approach in Collaborative Cross mice. Article Snippet: The list of probe sets in each class was subject to pathway enrichment analysis using the Tox Analysis module in Article Title: Transient Changes in Hepatic Physiology That Alter Bilirubin and Bile Acid Transport May Explain Elevations in Liver Chemistries Observed in Clinical Trials of GGF2 (Cimaglermin Alfa). Article Snippet: GGF2 is a recombinant human neuregulin-1b in development for chronic heart failure.. Phase 1 clinical trials of GGF2 were put on hold when transient elevations in serum aminotransferases and total bilirubin were observed in 2 of 43 subjects who received single doses of GGF2 at 1.5 or 0.378 mg/kg.. However, aminotransferase elevations were modest and not typical of liver injury sufficient to result in elevated serum bilirubin. |